Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA Registry

Abstract

Aims

We aimed to document the drug management of patients at high cardiovascular risk in daily practice, with the special focus on lipid-lowering treatment.

Methods and results

In this prospective noninterventional study in 2387 outpatient centers throughout Germany, a total of 13,942 high-risk patients (mean age 65.7 years, 61.6% males) were treated with simvastatin 40 mg/day at entry as monotherapy. All patients were followed up for 12 months in terms of drug utilization, laboratory values, target attainment, and clinical events (including death, hospitalization, vascular events, and dialysis). Patients had coronary heart disease in 35.0%, diabetes mellitus in 24.4%, and the combination of coronary heart disease plus diabetes mellitus in 25.7%. In 21% of patients, a cholesterol absorption inhibitor was added to statin therapy at the entry visit, and in 23%, this was added at the follow up visit 6 months later. The target values for low-density lipoprotein-cholesterol (<2.6 mmol/L) were reached by 31.8% of patients at entry and by 50.0% at the end of this registry after 12 months. Mean blood pressure decreased (from 135.9/80.5 mmHg at baseline) by 3.1/1.9 mmHg after 12 months. In patients with documented diabetes, the targeted glycated hemoglobin (HbA_1c <6.5%) was reached by 33.5% at baseline and by 40.0% after 12 months. Clinical events occurred in 11.7% of patients between baseline and month 6, and in 12.0% between months 6 and 12.

Conclusion

In patients at high risk for cardiovascular events, comprehensive management under daily practice conditions leads to improvement of lipid, glucose, and blood pressure parameters. There is a need to improve secondary prevention among high-risk patients.

Keywords:

• dyslipidemia
• observation
• treatment
• risk factors
• coronary heart disease
• cardiovascular disease

Disclosure

JRS serves as a consultant for MSD/ESSEX and received lecture fees by MSD/ESSEX, Roche, Sanofi, Genzyme and B Braun. DP has received consultancy honoraria from MSD, Sanofi, Pfizer and Novartis. KB is a former employee of MSD; CJ and BK are current, full-time employees of MSD. Apart from this, the authors report no conflicts of interest.

Acknowledgments

The registry was supported by MSD SHARP and DOHME GmbH, Haar, Germany.